Healthcare >> CEO Interviews >> July 28, 2003
STEVEN V. KING was appointed President and Chief Executive Officer of
Peregrine Pharmaceuticals, Inc., in March 2003 and was previously Chief
Operating Officer. Since January 2000 Mr. King has also served as the
President of Peregrine's wholly owned contract manufacturing subsidiary,
Avid Bioservices. Mr. King joined Peregrine in 1997 in the capacity of
Director of Research and Development and has also served as Senior
Director of Research and Development and Vice President of Technology
and Product Development prior to becoming Chief Operating Officer in
August 2002. Mr. King was previously employed at a corporation that was
developing vascular targeting agents (VTA) which was acquired by
Peregrine in 1997. Mr. King previously worked with Dr. Phillip Thorpe,
inventor of the VTA technology, at the University of Texas Southwestern
Medical Center at Dallas and is a co-inventor on over 25 US and foreign
patent applications in the VTA area. Profile
explain the concept of collateral targeting technologies?
Mr. King: Peregrine is a public company based in Tustin,
